Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Alexion_Pharmaceuticals
|
| gptkbp:acquisitionYear |
2020
|
| gptkbp:focus |
treatment of infectious diseases
development of small molecule drugs treatment of complement-mediated diseases |
| gptkbp:founded |
1998
|
| gptkbp:founder |
gptkb:Milton_H._Werner
|
| gptkbp:headquartersLocation |
New Haven, Connecticut, United States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Achillion Pharmaceuticals
|
| gptkbp:industry |
gptkb:biotechnology
pharmaceuticals |
| gptkbp:notableProduct |
gptkb:ACH-1625
gptkb:ACH-3102 gptkb:ACH-4471 |
| gptkbp:status |
defunct
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:ACHN
|
| gptkbp:website |
www.achillion.com
|
| gptkbp:bfsParent |
gptkb:Frank_Verwiel
|
| gptkbp:bfsLayer |
6
|